Emergent BioSolutions Provides 2026 Revenue Guidance and Raises Adjusted Gross Margin Outlook
Emergent BioSolutions (EBS) has issued its financial outlook for 2026, projecting revenue in the range of $600 million to $645 million. Additionally, the company raised its adjusted gross margin guidance to a range of 45% to 47%, signaling improved operational efficiency and profitability expectations. During the Q3 earnings call, CEO Joseph Papa addressed the company's current focus on execution and an upcoming leadership transition. Specifically, long-time CFO Rich [Last Name Not Provided] announced his retirement after a 17-year career as a public company CFO, including nine years at Emergent.
Tickers: $EBS
Topics: CFO Retirement Earnings Call Leadership Transition
Read the full article at Seeking Alpha
Part of the story Pfizer Raises 2026 Revenue Guidance Amid Strong Growth in Acquired Products (18 articles)